Patents by Inventor Stephen John Skittrall

Stephen John Skittrall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for the preparation of 6-?,9-?-difluoro-17-?-((2-furanylcarbonyl)oxy)-11-?-hydroxy-16-?-methy1-3-oxo-androsta-1,4-diene-17-?- -carbothioic acid S-fluoromethyl
    Patent number: 8309713
    Abstract: A novel process for preparing a compound of formula (I) which comprises converting a compound of formula (II) to a compound of formula (I) via a compound of formula (III), or a salt thereof, without isolating any intermediates.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: November 13, 2012
    Assignee: Glaxo Group Limited
    Inventors: Malcolm Brian Berry, Mark Jason Hughes, David Parry-Jones, Stephen John Skittrall
  • Process for the Preparation of 6-alpha,9-alpha-difluoro-17-alpha-((2-furanylcarbonyl)oxy)-11-beta-hydroxy-16-alpha-methyl-3-oxo-androsta-1,4-diene-17-beta- -carbothioic acid S-fluoromethyl
    Publication number: 20090118495
    Abstract: A novel process for preparing a compound of formula (I) which comprises converting a compound of formula (II) to a compound of formula (I) via a compound of formula (III), or a salt thereof, without isolating any intermediates.
    Type: Application
    Filed: June 13, 2007
    Publication date: May 7, 2009
    Applicant: GLAXO GROUP LIMITED
    Inventors: Malcolm Brian Berry, Mark Jason Hughes, David Parry-Jones, Stephen John Skittrall
  • Medicaments
    Patent number: 5705520
    Abstract: The present invention, relates to 3-?2-(dimethylamino)ethyl!-N-methyl-1H-methanesulphonamide sulphate salt (2:1) and pharmaceutically acceptable solvates thereof, and to pharmaceutical compositions containing same. The compound is useful in the treatment of conditions associated with cephalic pain, in particular migraine. The pharmaceutical compositions are particularly useful as intranasal formulations.
    Type: Grant
    Filed: May 21, 1996
    Date of Patent: January 6, 1998
    Assignee: Glaxo Group Limited
    Inventors: Joanne Craig, Derek Leslie Crookes, Stephen John Skittrall